Literature DB >> 12180895

Treatment of mucocutaneous presentations of herpes simplex virus infections.

Arjen F Nikkels1, Gérald E Pièrard.   

Abstract

Infections by herpes simplex virus (HSV) types I and II are diverse and quite frequent. After primary infection, the virus establishes a life-long latency in the sensory ganglia and recrudescences may occur at an unpredictable rate. Recurrent labial and genital herpes infections represent the majority of clinical manifestations of HSV infections. Their management is currently well established using evidence-based medicine data. Primary labial herpes is generally not treated with antivirals in otherwise healthy children, although intravenous aciclovir may be offered in severe primary infections, particularly in the immunocompromised patient. The decision whether or not to treat recurrent labial herpes should be evaluated individually and depends on the frequency and severity of relapses, the impairment of the quality of life, and the cost of therapy. Patients with mild disease may benefit from topical therapy, and those with severe and frequent recurrences may be considered for intermittent or long-term oral antiviral therapy. Primary genital herpes is treated with oral or intravenous antivirals, depending on the severity of the infection and associated symptoms. Recurrent genital herpes can be managed with episodic short courses of oral antivirals in patients whose recurrences are moderate to severe and rare, and have a clear prodrome. Patients with >5 episodes/year, severe recurrences or unrecognisable prodromes may be best managed with long-term suppressive antiviral prophylaxis. HSV is also responsible for a variety of other clinical manifestations, including herpetic whitlow, neonatal infection, disseminated and atypical cutaneous infections, traumatic herpes, eczema herpeticum, and HSV-associated erythema multiforme. HSV infection may also represent a complication following cosmetic procedures of the oro-facial region, surgical and dental interventions, sun exposure and burns. Precise treatment guidelines for these HSV infections are not firmly established.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12180895     DOI: 10.2165/00128071-200203070-00004

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  8 in total

Review 1.  The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II.

Authors:  L El Hayderi; A Rübben; A F Nikkels
Journal:  Hautarzt       Date:  2017-12       Impact factor: 0.751

Review 2.  [The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II. German version].

Authors:  L El Hayderi; A Rübben; A F Nikkels
Journal:  Hautarzt       Date:  2017-03       Impact factor: 0.751

Review 3.  Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeutics.

Authors:  Arif Azam Khan; Ruchi Srivastava; Patricia Prado Lopes; Christine Wang; Thanh T Pham; Justin Cochrane; Nhi Thi Uyen Thai; Lucas Gutierrez; Lbachir Benmohamed
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

Review 4.  Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes.

Authors:  Dene Simpson; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Herpes labialis manifesting as recurrent erythema multiforme and solitary ulcer on face.

Authors:  Biju Vasudevan; Ashish Bahal; Vinod Raghav
Journal:  J Glob Infect Dis       Date:  2009-01

6. 

Authors:  María José Monedero Mira; Manuel Batalla Sales; Concepción García Domingo; María José Monedero Mira; Belén Persiva Saura; Gloria Rabanaque Mallen; Lledó Tárrega Porcar
Journal:  FMC       Date:  2016-04-26

7.  Herpes simplex virus reactivation and dental procedures.

Authors:  L El Hayderi; P Delvenne; E Rompen; J M Senterre; A F Nikkels
Journal:  Clin Oral Investig       Date:  2013-04-21       Impact factor: 3.573

8.  Eczema herpeticum subsequent to septic shock in early pregnancy: a first case report.

Authors:  Kiichiro Furuya; Yuki Takemoto; Hiroki Kurahashi; Harue Hayashida; Sho Fujiwara; Saya Yamashita; Yangsil Chang; Hiroaki Tsubouchi; Kayoko Shikado; Kazuhide Ogita
Journal:  BMC Infect Dis       Date:  2021-12-14       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.